Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Nov 2023 Results assessing the effect of lanifibranor on IR in liver, muscle and adipose tissue in relation to intrahepatic triglyceride (IHTG) content presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 13 Jun 2023 According to an Inventiva Pharma Media Release, additional secondary endpoints including a series of markers of cardiometabolic health are anticipated to be presented by Dr. Cusi in upcoming scientific conferences and publications